UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 5.

Mach, F; Gabay, C; Buchs, N; Dudler, J; Gencer, B; Hasler, P; Matter, C; Michel, B A; von Kempis, J; Zufferey, P (2015). Consensus guidelines on the cardiovascular risk management in patients with rheumatoid arthritis. Cardiovascular Medicine, 4(18):127-133.

Finckh, A; Ciurea, A; Brulhart, L; Möller, B; Walker, U A; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2010). Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Annals of the Rheumatic Diseases, 69(2):387-393.

Finckh, A; Dudler, J; Wermelinger, F; Ciurea, A; Kyburz, D; Gabay, C; Bas, S (2010). Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint, Bone, Spine, 77(4):313-318.

Dudler, J; Finckh, A; Kyburz, D; Langenegger, T; Möller, B; Schmiedel, U; Walker, U A (2010). Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Medical Weekly, (140):w13073.

Finckh, A; Ciurea, A; Brulhart, L; Kyburz, D; Möller, B; Dehler, S; Revaz, S; Dudler, J; Gabay, C (2007). B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis and Rheumatism, 56(5):1417-1723.

This list was generated on Wed Jul 26 18:38:14 2017 CEST.